MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

PURPOSE: Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%-60% of LGSOCs. The purpose of this study was to evaluate binimetinib, a potent MEK1/2 inhibitor with demonstrated ac...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Monk, Bradley J., Grisham, Rachel N., Banerjee, Susana, Kalbacher, Elsa, Mirza, Mansoor Raza, Romero, Ignacio, Vuylsteke, Peter, Coleman, Robert L., Hilpert, Felix, Oza, Amit M., Westermann, Anneke, Oehler, Martin K., Pignata, Sandro, Aghajanian, Carol, Colombo, Nicoletta, Drill, Esther, Cibula, David, Moore, Kathleen N., Christy-Bittel, Janna, del Campo, Josep M., Berger, Regina, Marth, Christian, Sehouli, Jalid, O’Malley, David M., Churruca, Cristina, Boyd, Adam P., Kristensen, Gunnar, Clamp, Andrew, Ray-Coquard, Isabelle, Vergote, Ignace
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7655017/
https://ncbi.nlm.nih.gov/pubmed/32822286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01164
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares